Technology evaluation: CN-706, Calydon Inc

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 6, 2000, Pages 703-708

  Doehn, C ^a   Jocham, D ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CN 706; CN 787; UNCLASSIFIED DRUG;

ADENOVIRUS; ADVANCED CANCER; ARTICLE; BIOTECHNOLOGY; CANCER RECURRENCE; CELL DIVISION; CELL KILLING; CLINICAL TRIAL; DRUG MECHANISM; DRUG SYNTHESIS; ENHANCER REGION; FEVER; FLU LIKE SYNDROME; GENE THERAPY; GENE TRANSFER; HUMAN; LETHAL DOSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION;

ADENOVIRIDAE; ANIMALS; BIOTECHNOLOGY; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 0034520357     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Advances and trends in hormonal therapy for advanced prostate cancer
2. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
3. Calydon - Company background information
4. Prostate-specific antigen expression is regulated by an upstream enhancer
5. AV vector pitted against prostate cancer
6. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
7. Replicating vectors for gene therapy of cancer: Risks, limitations and prospects
8. Drug development pipeline: Calydon's prostate cancer therapy
9. Gene therapy - Promises, problems and prospects
10. Calydon begins US clinical trial of the first tissue-specific viral therapeutic for prostate cancer
11. Calydon announces issuance of three patents for technologies for targeting and destroying tumors including prostate cancer
12. American Association for Cancer Research - 90th Annual Meeting (Part VII), Philadelphia, PA, USA
13. Prostate tumor-specific cytolysis and tumor eradication by intravenous administration of CN-787, and attenuated replication competent adenovirus containing E3
14. Synergism of ionizing radiation and gene therapy with the replication competent CN-706 adenovirus in the LAPC-4 prostate cancer cell line
15. Calydon announces issuance of two patents for technologies that destroy cancer tumors, including prostate cancer
16. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
17. Calydon: Experimental drug could be powerful treatment against prostate cancer
18. Calydon Inc: Prostate cancer patients begin clinical trials of an experimental drug that infects and destroys only cancer cells
19. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs
20. Gene therapy - The future is here: A guide to the practicing urologist
21. Management of hormone refractory prostate cancer: Current standards and future prospects
22. An analysis of watchful waiting for clinically localized prostate cancer
23. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer
24. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
25. Gene therapy for prostate cancer: New perspectives on an old problem
26. Gene therapy of prostate cancer: P53, suicidal genes, and other targets
27. Clinical application for gene therapy in prostate cancer
28. Training viruses to attack cancers
29. Molecular and clinical activity of CN-706, a PSA-selective oncolytic Ad5 vector in a phase trial in locally recurrent prostate cancer following radiation therapy
30. The natural history of early prostate cancer and the impact of endocrine treatment
31. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using non-steroidal antiandrogens
32. Estrogens in the treatment of prostate cancer
33. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
34. Maximal androgen blockade: Final analysis of EORTC phase III trial 30853
35. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or longterm (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer
36. Hormonal therapy in the management of prostate cancer: From Huggins to the present
37. Some aspects of the biology and endocrinology of prostate cancer
38. Evaluation and management of the man who has falled primary curative therapy for prostate cancer
39. Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer
40. Controversies in the management of advanced prostate cancer
41. Calydon Inc: Clinical trials begin for men with metastatic prostate cancer
42. Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic
43. Calydon Inc: Experimental prostate cancer drug demonstrates entitumor activity and acceptable safety profile
44. Cell proliferation, DNA repair and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation
45. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN-706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
46. Bioactivity of CN-706, a PSA-specific oncolytic adenoviral vector: A phase I trial of in vivo gene therapy for locally-recurrent prostate cancer following radiation therapy
47. Results of a phase I study of CN-706, a replication-competent cytolytic adenovirus, for the treatment of adenocarcinoma of the prostate which is locally-recurrent following radiation therapy
48. Molecular genetics of prostate cancer
49. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization
50. Gene therapy for prostate cancer: Where are we now?
51. A randomized comparison of Casodex (Bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer
52. Methods of gene delivery
53. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
54. Advances in adenoviral vectors: From genetic engineering to their biology
55. Development and application of adenoviral vectors for gene therapy of cancer